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161Outcomes of reoperative open or endovascular
interventions to treat patients with failing open
mesenteric reconstructions for mesenteric ischemia
Karina S. Kanamori, MD,a Gustavo S. Oderich, MD,a Javairiah Fatima, MBBS,b Timur Sarac, MD,b
Stephen Cha, MS,c Manju Kalra, MBBS,a Randall De Martino, MD,a and Thomas C. Bower, MD,a Rochester,
Minn; and Cleveland, Ohio
Objective: Outcomes of reinterventions for failing mesenteric open reconstructions (ORs) have not been described.
Mesenteric reoperative ORs (R-ORs) are challenging because of excessive scar and more advanced mesenteric disease. The
purpose of this study was to evaluate outcomes of R-ORs and endovascular revascularization (ER) in patients with
stenosis or occlusion of mesenteric grafts.
Methods: We reviewed 701 patients treated for chronic mesenteric ischemia (CMI) in two academic centers from 1991 to
2013. Clinical data and outcomes of patients treated for failing ORs with R-ORs or ERs were included in the analysis. A
1:2 case-control matching was used to analyze outcomes of R-ORs compared with patients who underwent their ﬁrst-time
ORs for CMI. End points were early and late mortality, morbidity, patency rates, and freedom from symptom recurrence
and reintervention.
Results: Therewere 47patients (ﬁvemen, 42women;mean age, 58613 years)with failingORswhowere treated byR-ORs.
Clinical presentation was CMI in 38 patients (81%) or acute mesenteric ischemia (AMI) in nine (19%). Reinterventions
included R-ORs in 28 patients (19 CMI and nine AMI) and ERs in 19, all for CMI. Early mortality was 22% in patients
treated by R-ORs for AMI. There were no early deaths among patients treated for CMI with R-OR or ER. Early morbidity
was 78% for R-ORs in patients treated for AMI.Morbidity was signiﬁcantly higher for R-ORs than for ERs in patients with
CMI (63% vs 16%; P < .05). Mean follow-up was 50 6 60 months. Patient survival at 5 years was 60% 6 8% for the entire
cohort. Primary and secondary patency at 1 year were 61%6 10% and 92%6 8% for R-ORs (P[ .34) and 77%6 10% and
100% for ERs (P[ .41). Freedom from symptom recurrence and reinterventions at 1 year was 88%6 6% and 87%6 7% for
R-ORs and 83%6 8% and 71%6 10% for ERs. Case case-control (1:2) matching showed R-ORwas associated with similar
early mortality andmorbidity and also similar freedom from recurrence and reintervention but with lower primary patency
rates at 1 year compared with ﬁrst time ORs (66% 6 11% and 94% 6 5%; P < .05).
Conclusions: R-OR or ER interventions for failing mesenteric ORs carry similar mortality, recurrence, and reintervention
rates. Early morbidity is lower with ER compared with R-OR. R-ORs are associated with similar morbidity and mortality
and lower primary patency compared with ﬁrst-time OR for CMI. (J Vasc Surg 2014;60:1612-9.)Since the ﬁrst successful mesenteric endarterectomy by
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2most centers, endovascular therapy has surpassed open
surgery as the ﬁrst treatment, being used in >80% of
patients with chronic mesenteric ischemia (CMI).2,3 The
treatment paradigm changed despite the lack of prospective
randomized data comparing open and endovascular tech-
niques. Systematic reviews of single-center reports have
shown that endovascular revascularization (ER) is associ-
ated with decreased morbidity compared with open
repair.3,4 In contrast, mesenteric bypass offers improved
patency, with lower rates of reinterventions and less symp-
tom recurrence.2-12
Despite its superior durability, w10% to 20% of
patients treated by mesenteric open reconstruction (OR)
develop recurrent symptoms from graft stenosis or occlu-
sion.3,6 Angioplasty and stenting is appealing in these
patients because of the technical difﬁculties imposed by
the surgical scar and the risk of damaging important collat-
erals. Nonetheless, ER is not always possible. In the acute
setting, some patients need abdominal exploration to treat
bowel gangrene or perforation. The outcomes of reinter-
ventions performed to treat failing mesenteric grafts has
not been well described, with only scarce case reports
Fig 1. A, Occluded bifurcated mesenteric graft in a patient with acute mesenteric ischemia (AMI) was treated by
emergency revision and thrombectomy. B, After exposure of the distal graft anastomosis, a longitudinal graftotomy was
performed starting at the distal graft and extending to the native superior mesenteric artery (SMA). C, Catheter
thrombectomy was used, (D) followed by revision of the distal anastomosis by patch angioplasty. E, Follow-up
computed tomography angiography with patent graft limb. Reprinted by permission of Mayo Foundation for Medi-
cal Education and Research. All rights reserved.
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was to evaluate the outcomes of reoperative ORs (R-ORs)
and ERs to treat patients with failing mesenteric grafts or
prior mesenteric transaortic endarterectomy.
METHODS
The studywas approvedby theMayoClinicMedicalCol-
lege and Cleveland Clinic Foundation Institutional Review
Boards. Informed consentwas obtained from all study partic-
ipants. The clinical data on all consecutive patients treated by
mesenteric OR or ER at the Mayo Clinic and Cleveland
Clinic Foundation from 1991 to 2013 were retrospectively
reviewed using a standardized database. The analysis
includedpatientswhounderwentR-ORsorERs (angioplasty
alone or stenting, or both) to treat failing mesenteric grafts,
anastomotic, or surgical endarterectomy sites because of
symptomatic restenosis or occlusion. The study excluded pa-
tients treated for median arcuate ligament syndrome and
those who had primary endovascular interventions.
Demographics, clinical characteristics, radiologic data,
and operative data were obtained from the medical records.
The early postoperative period was deﬁned as occurring
#30 days or within the hospital stay if >30 days. The
late follow-up period was deﬁned as >30 days or dismissal
from the hospital until the last available clinical examina-
tion or correspondence. Follow-up consisted of clinical ex-
amination and duplex ultrasound imaging every 6 months
during the ﬁrst year and annually thereafter. Late follow-up
data were obtained from review of medical records, corre-
spondence with patient or referral physician, telephoneinterview, or questionnaire. Technical success was deﬁned
by <30% residual stenosis on completion angiography or
an intraoperative duplex ultrasound assessment demon-
strating a widely patent bypass graft.
Treatment selection. Selection of open or endovascu-
lar approach was left to the discretion of the treating physi-
cian. Endovascular therapy evolved during the study period
from primary use of angioplasty alone or hand-mounted
stents before 1998 to preferential use of premounted
stents since 1999. For patients who presented with acute
symptoms and peritoneal signs or gangrenous or perforated
bowel, an exploratory laparotomy and R-OR was indicated.
Surgical thrombectomy of the graft with patch angioplasty
was the preferred treatment in these patients (Fig 1).
Patients who were considered not suitable for ER
because of ﬂush or long-segment occlusions with a large
thrombus burden were treated by R-OR. For low-risk pa-
tients, a supraceliac aorta-to-celiac and superior mesenteric
artery (SMA) bypass (Fig 2) was frequently used, whereas
higher-risk patients or those with a diseased supraceliac
aorta were treated by retrograde bypass based in the iliac
artery or infrarenal aorta. Revision of the distal anastomosis
with patch angioplasty was reserved for patients with focal
stenosis of the distal anastomotic site not suitable or resis-
tant to ER. Alternatively, primary stenting was used when-
ever possible in patients with CMI from focal stenosis or
occlusion of a graft limb (Fig 3).
Statistical analysis. Data were analyzed using the So-
ciety for Vascular Surgery reporting standards.15 End
points included early and late mortality, morbidity, patency
Fig 2. A, Computed tomography angiography of a patient with recurrent symptoms of chronic ischemia due to (B)
occluded bifurcated supraceliac aorta-to-celiac and superior mesenteric artery (SMA) bypass graft. C, A redo bifurcated
graft was performed from the supraceliac aorta. D, After exposure of the distal SMA limb anastomosis, a longitudinal
graftotomy was made, followed by excision of the old graft and thrombectomy. Redo bypass was performed with
(E) a distal anastomosis to the SMA and (F) a second limb to the hepatic artery. G, Repeat computed tomography
angiography revealed a widely patent graft. Reprinted by permission of Mayo Foundation for Medical Education and
Research. All rights reserved.
Fig 3. A, Selective angiography of the celiac limb of a stenosed aortomesenteric graft. The lesion was (B) crossed by
wire and (C) treated by angioplasty and stenting using balloon-expandable stent.
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vention. To evaluate the effect of R-OR compared with
ﬁrst-time OR to treat CMI, the greedy algorithm was used
to identify two OR controls for each R-OR case. Each pair
was matched by age, gender, and cardiovascular riskfactors, including hypertension, diabetes, coronary artery
disease, hyperlipidemia, tobacco use, chronic kidney dis-
ease, dialysis, and chronic pulmonary disease. Categoric
variables were analyzed with the Pearson c2 or the Fisher
exact test. Differences between means were analyzed with
Table I. Clinical characteristics of patients treated
for failing mesenteric open reconstructions (ORs)
by reoperative OR (R-OR) and endovascular
revascularization (ER)
Characteristics
Overall
(N ¼ 47)
R-OR
(n ¼ 28)
ER
(n ¼ 19)
P valueMean 6 SD or No. (%)
Demographics
Age, years 58 6 13 60 6 11 55 6 17 .26
Female gender 5 (11) 2 (7) 3 (16) .35
Cardiovascular risk
factors
Hypertension 27 (57) 17 (61) 10 (53) .58
Diabetes 6 (13) 4 (14) 2 (11) .7
Hyperlipidemia 22 (47) 12 (43) 10 (53) .51
Tobacco 30 (64) 18 (64) 12 (63) .69
PVD 15 (32) 9 (32) 6 (32) .97
CAD 11 (23) 8 (29) 3 (16) .31
CHF 3 (6) 2 (7) 1 (5) .8
CVD 7 (15) 4 (14) 3 (16) .89
Renal failure 5 (11) 3 (11) 2 (11) .98
COPD 5 (11) 3 (11) 2 (11) .98
Clinical presentation
Abdominal pain 46 (98) 28 (100) 18 (95) .22
Postprandial pain 26 (57) 12 (44) 14 (74) .049
Food fear 15 (33) 8 (30) 7 (37) .61
Nausea and/or
vomiting
17 (38) 10 (38) 7 (37) .91
Weight loss 25 (54) 12 (44) 13 (68) .11
CAD, Coronary artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CVD, cerebrovascular disease; PVD,
peripheral vascular disease; SD, standard deviation.
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appropriate. Data were analyzed using SAS 9.3 software
(SAS Institute Inc, Cary, NC). A two-sided P < .05 was
used to determine statistical signiﬁcance.
RESULTS
Study patients
There were 701 patients treated for mesenteric artery
disease, including 238 who had OR and 463 treated by
ER. From this group, 47 patients (7%) treated by interven-
tions for failing ORs were included in the analysis (Table I).
There were ﬁve male (11%) and 42 female (89%) patients
with a mean age of 58 6 13 years. Treatment in patients
with failing ORs included R-OR in 28 patients and ER
in 19.
Clinical presentation
Clinical presentation was CMI in 38 patients (81%),
19 with R-OR and 19 with ER, and acute mesenteric
ischemia (AMI) in nine (19%), all R-OR. The most
common symptoms were recurrent abdominal pain in
46 patients (98%), weight loss in 25 (54%) and food fear
in 15 (33%). The mean time from the initial OR was 3 6
4 years. Symptom duration averaged 5 6 7 months among
patients treated for chronic symptoms and <24 hours in
those with acute presentation. Cardiovascular risk factorsincluded hypertension in 27 patients (57%), coronary artery
disease in 11 (23%), and chronic pulmonary disease and
stage IV or V chronic kidney disease in ﬁve (11%) each.
Index mesenteric OR
The initial OR consisted of mesenteric bypass in 40 pa-
tients and transaortic mesenteric endarterectomy in seven.
Fifty-eight arteries were reconstructed. Bypasses were
based from the supraceliac aorta in 33 patients, iliac arteries
in ﬁve, and infrarenal aorta in one. One patient received a
SMA interposition graft. At the time of recurrent symp-
toms, all patients had three-vessel mesenteric artery disease.
Among 12 patients who originally had a single-vessel
bypass, 11 grafts were occluded and one had high-grade
stenosis. Of the 23 patients treated by bifurcated grafts,
19 had stenosis or occlusion of both limbs, and four had
isolated SMA limb occlusion.
Treatment
Mesenteric R-OR. Mesenteric R-OR was performed
under general endotracheal anesthesia. A midline transper-
itoneal approach was used in 26 patients and a bilateral
subcostal incision in two. All patients treated by R-OR
had graft occlusion, with chronic symptoms in 19 patients
and acute presentation in nine who had peritoneal signs
and required abdominal exploration to rule out bowel
gangrene or perforation. A total of 40 mesenteric arteries
were reconstructed, including 26 SMAs, 12 celiac arteries,
and two inferior mesenteric arteries. Single-vessel revas-
cularization was performed in 17 patients (61%), two-
vessel in 10 (36%), and three-vessel in one (3%).
Reconstruction techniques included 15 patients treated
by bypass grafts with inﬂow based from the supraceliac
aorta in 13 and the infrarenal aorta or iliac artery in one
each. Graft conduit was polyester in 12 patients and
saphenous vein in three.
Eleven patients underwent mesenteric graft thrombec-
tomy, with patch angioplasty in three or interposition graft
in two. Bovine pericardial patch angioplasty was used in
two patients to revise the distal anastomosis of a graft
with no thrombectomy. Among patients treated for AMI,
one required segmental bowel resection and one under-
went a second-look laparotomy. Postoperative medical
therapy consisted of aspirin in 15 patients (54%), warfarin
in eight (29%), and clopidogrel alone in two (7%).
ER. ER was used whenever possible to treat focal graft
stenosis or occlusion. The procedure was performed using
brachial artery access in 14 patients (74%) or a femoral ar-
tery approach in ﬁve (26%). A total of 25 mesenteric grafts
or native arteries were treated with angioplasty alone in 14
or primary stenting in 11. The arterial segment treated was
within the graft alone in 19, the native artery in ﬁve, or an
anastomosis in one. A total of 14 SMAs and 11 celiac ar-
teries were treated. One vessel was revascularized in 13 pa-
tients (68%) and two vessels were revascularized in six
(32%). Technical success was 100%. Medical therapy con-
sisted of aspirin in 13 patients (68%), clopidogrel in 10
(53%), and warfarin in ﬁve (26%).
Table II. Early morbidity of patients treated for failing
mesenteric open reconstructions (ORs) by reoperative
OR (R-OR) and endovascular revascularization (ER)
Early outcomes
Overall
(N ¼ 47)
R-OR
(n ¼ 28)
ER
(n ¼ 19)
P
valueMean 6 SD or No. (%)
ICU length of
stay, days
7 6 11 11.5 6 12 0.5 6 1 <.001
Complication
Any 22 (48) 19 (68) 3 (16) <.001
Cardiac 3 (7) 3 (11) 0 (0) .13
Respiratory 9 (20) 9 (33) 0 (0) .005
Intubated >10 days 1 (3) 1 (4) 0 (0)
Pneumonia 3 (8) 3 (12) 0 (0)
Renal 4 (9) 4 (15) 0 (0) .08
Neurologic 2 (4) 2 (7) 0 (0) .23
Gastrointestinal 4 (9) 4 (15) 0 (0) .08
Others 13 (29) 10 (38) 3 (16) .1
ICU, Intensive care unit; SD, standard deviation.
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There were two early deaths among the nine patients
(22%) treated by R-OR for AMI. The patients died on
postoperative days 28 and 21 of multisystem organ failure
(MOF) after successful thrombectomy and redo bypass.
Postoperative complications developed in 22 patients
(47%) overall (Table II); early morbidity was 78% among
patients treated by R-OR for AMI. Patients treated by R-
OR (68%) had signiﬁcantly higher complication rate than
those who had ER (16%; P < .001), including analysis
those treated for CMI (63% vs 16%, respectively; P < .05).
All patients had immediate symptom improvement af-
ter revascularization, independent of the technique or clin-
ical presentation. Hospital stay averaged 18 6 14 days for
R-OR and 3 6 3.5 days for ER (P < .001). Among pa-
tients treated for CMI, hospital stay was 16 6 12 days
for R-OR and 3 6 3.5 days for ER (P < .001). All target
mesenteric arteries were patent at dismissal.
Late outcomes
Patient survival. Follow up averaged 50 6 60 months
(range, 0-355 months) and was complete for the entire
cohort. Imaging studies to objectively assess vessel patency
were available in 40 of the 45 survivors (89%); of whom, 22
were treated by R-OR and 18 treated by ER. Patient sur-
vival at 5 years was 60% 6 8% for the entire cohort and
was similar among patients treated by ER (80% 6 10%)
compared with OR (45% 6 11%; P ¼ .10). Survival at
1 year was 83% 6 6% among patients treated for CMI and
56%6 17% for those who presented acutely (P ¼ .04). Sur-
vival in patients treated for CMI at 1 year was similar for ER
(89% 6 8%) and R-OR (79% 6 10%; P ¼ .16).
Freedom from recurrent symptoms, restenosis, and
reinterventions. Recurrent symptoms developed in 12 pa-
tients, including ﬁve treated by R-OR and seven treated by
ER (P ¼ .18). Freedom from symptom recurrence at 1 year
was 88% 6 6% for R-OR and 83% 6 8% for ER (P ¼ .67;Fig 4, A). Restenosis or occlusion was noted in 22 arteries
treated by R-OR and 12 that were treated with angioplasty
or stents. The primary and secondary patency at 1-year was
61% 6 10% and 92% 6 8% for R-ORs and 77% 6 10% and
100% for ERs (P ¼ .34). Freedom from any reinterventions
after the ﬁrst R-OR or ER reintervention at 1 year was
87% 6 7% for R-ORs and 71% 6 10% for ERs (P ¼ .34;
Fig 4, B).
Comparison of ﬁrst-time OR vs R-ORs. The clinical
data of 19 patients treated by R-OR for chronic symptoms
were matched to 35 control patients who underwent their
ﬁrst OR (Supplementary Table, online only). Compared
with the ﬁrst-time OR group, patients treated by R-OR
had similar 30-day morbidity (40% vs 63 %, P ¼ .15), 30-
day mortality (3% vs 0%), and 1-year freedom from recur-
rence (97% vs 88%; Supplementary Fig 1, online only) and
reintervention (93% vs 77%; Supplementary Fig 2, online
only). Primary patency at 1 year was signiﬁcantly lower for
R-OR (66%) than for OR (93%; P ¼ .006; Supplementary
Fig 3, online only).
DISCUSSION
Despite an abundant literature on the results of mesen-
teric ORs, outcomes of reinterventions performed for
failing surgical grafts are lacking. Because intervention for
mesenteric ischemia is rare compared with other vascular
operations, this study combined the experience of two
large academic centers during 10-year and 20-year periods
to increase the numbers of patient with this problem to
make meaningful comments. Even with this methodology,
only 47 patients could be identiﬁed among 701 treated for
mesenteric ischemia at both institutions.
Our treatment of failing grafts parallels the same para-
digm shift we have seen in the treatment of de novo mesen-
teric artery lesions during the last 20 years, in that
endovascular therapy is offered as ﬁrst-line treatment.
Open surgery now is relegated to patients who are not can-
didates for endovascular therapy because of anatomic con-
straints or because the interventions fail.2 However, open
surgery is needed when patients with graft occlusions pre-
sent with AMI, as evidenced by the nine such patients in
this series who presented with advanced ischemia, where
time to restoration of blood ﬂow is of the essence.
Similar to patients who undergo ﬁrst-time interven-
tions, the choice of treatment is determined by clinical pre-
sentation and anatomy, such as origin of the graft and the
distal target artery, lesion length, graft occlusion vs steno-
sis, native arterial calciﬁcation, or distal side branch involve-
ment. Selecting endovascular therapy as the ﬁrst option to
treat all restenosis or occlusions of mesenteric grafts seems
logical if this option is possible. The advantages are
numerous, notably local anesthesia, no need for laparot-
omy or dissection in a scarred ﬁeld, and lower morbidity
and mortality, particularly in the elderly or frail patient.
Focal stenoses are ideally suited for angioplasty and stent-
ing. Although more complex lesions can be treated by
endovascular therapy, restenosis occurs if the technical
result is suboptimal.16 Graft occlusions can be treated by
Fig 4. Kaplan-Meier survival estimates of freedom from (A) symptom recurrence and (B) reintervention in patients
treated by redo open reconstruction (R-OR, blue line) or by endovascular revascularization (ER, red line). The dotted
line indicates standard deviation >10%.
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of occlusion are more difﬁcult to treat.
A few technical points are noteworthy. The choice of
access for percutaneous interventions is determined by
the graft conﬁguration. For supraceliac grafts, brachial ar-
tery access provides better platform support and easier ac-
cess to the graft than femoral access. The latter is needed
in patients with retrograde grafts that originate from the
iliac arteries or infrarenal aorta.
Large thrombus burden within occluded grafts, the
presence of pseudointima resistant to balloon dilatation,
and lesion involvement of middle and distal SMA segments
were major limitations to ER. Nearly 60% of our patients
were not candidates for ER because of anatomic reasons.
Among patients with chronic symptoms, ER was used in
19 patients (50%), including angioplasty alone in 14 of
the 25 treated arteries (56%).
We acknowledge that angioplasty alone is not ideal in
these circumstances due to recoil and restenosis; preferably,
primary stenting should be selected with a balloon or self-
expandable stent, depending on the trajectory of the graft
and tortuosity. In this series, we did not use covered stents.
A recent study showed these stents are associated with less
restenosis and reintervention compared with bare-metal
stents in native arteries.17 Although covered stents have
not been studied in mesenteric grafts, the polytetraﬂuoro-
ethylene coverage may act as a physical barrier to neointima
or pseudointima. Unfortunately, primary stenting is not al-
ways possible because of lesion characteristics at the anasto-
motic site and beyond it.
However, even with the study limitations imposed by
improvements in endovascular technology covering the
time period of this analysis, our experience demonstrates
that angioplasty and stenting are not always possible and
that mesenteric R-OR has a major role for revasculariza-
tion. R-OR presents the challenges of dissection in a
scarred ﬁeld where normal anatomy can be distorted and
the potential to disrupt well-developed mesenteric collat-
eral arteries, which cause troublesome bleeding. Reopera-
tion on patients with failing grafts should be kept as
simple as possible. Similar to the approach we adopted
for primary mesenteric artery bypass, concomitant aorticreconstruction is avoided because of higher morbidity
and mortality than operations focused only on the mesen-
teric reconstruction.3
For patients who have recalcitrant lesions causing ste-
nosis at the distal anastomosis, most of the graft can be pre-
served and the anastomosis revised using a bovine or vein
patch (Fig 1). If the graft is occluded or diffusely narrowed,
a new bypass is planned after careful selection of inﬂow and
outﬂow sites. Our preference is for two-vessel reconstruc-
tion using a bifurcated graft based from the supraceliac
aorta when the patient is low risk and the anatomy is favor-
able (Fig 2).
A retrograde bypass based on the iliac artery or infrare-
nal aorta offers a good option, especially for elderly or high-
risk patients who cannot tolerate supraceliac clamping or
those with a prior supraceliac-based reconstruction.18 In
these cases, the SMA is usually the sole target. This
approach has particular utility in the acute setting, where
the shortest time to revascularization, avoidance of hemo-
dynamic swings, and simplicity should prevail. A retrograde
graft can be in a straight conﬁguration or as a C-shape to
allow antegrade ﬂow through the SMA, whichever lies
best. In the rare chronic patient with hostile anatomy and
the inability to get inﬂow from the abdominal aorta or iliac
arteries, some authors originate the bypass from the lower
thoracic or ascending aorta.19
The clinical data on mesenteric R-ORs are scarce.
Giswold et al19 reported the only clinical series of 22 pa-
tients treated from 1985 to 2002. In that study, operative
mortality was 6% for elective reconstructions. Primary graft
patency was 62%, which is similar to our patency of 66% at
1 year but less than what is observed for ﬁrst-time recon-
structions.20,21 Clearly, these patients need an intraopera-
tive assessment of technical outcome and more rigid
postoperative surveillance if patency is to be improved.
Given the paucity of clinical data, we compared the re-
sults of R-OR and ﬁrst-time OR for CMI. We found similar
morbidity and mortality at 30-days, despite the challenges
imposed by reoperative surgery. Redo mesenteric bypass
was associated with signiﬁcantly lower primary patency
rates but similar secondary patency rates compared with
ﬁrst-time reconstructions. This difference in primary
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culty and more extensive native disease in the R-OR group.
Late freedom from recurrence and reintervention were
similar, but the number of patients treated by redo bypass
for chronic symptoms was small. Endovascular interven-
tions for graft failure had similar freedom from recurrence
and reintervention compared with R-OR, but carried less
morbidity. Given the higher rate of restenosis and reinter-
vention reported when primary treatment of a mesenteric
artery stenosis is by ER, this ﬁnding may be explained by
selection bias. Patients who can be salvaged with angio-
plasty or stenting more often have graft stenosis and not
occlusion and have more favorable native artery anatomy.
Nonetheless, this study supports a strategy of ER ﬁrst,
whenever possible, to treat patients with failing mesenteric
grafts.
Most patients with mesenteric artery disease have
diffuse atherosclerosis, so it is not surprising that 5-year
survival is 60% to 70%. The 5-year survival of 60% 6 8%
in our study is similar to the 71% 6 4% rate reported by
Tallarita et al22 in 343 patients treated for CMI. The
main causes of death after mesenteric revascularization in
most reports are cardiac, malignancy, and pulmonary in
origin. Interestingly, recurrent mesenteric complications
are the fourth most common cause of death in 4% of pa-
tients. In this study, survival was signiﬁcantly decreased in
patients treated by R-OR compared with ﬁrst-time OR,
even after risk factors were controlled using propensity
score matching (82% for OR vs 43% for R-OR; P < .05).
Because the mean age of patients in this study was 58 years,
the lower survival may reﬂect more advanced atheroscle-
rosis at a younger age when the ﬁrst bypass was done.
Signiﬁcant changes have occurred in the treatment of
mesenteric artery disease during the last 20 years, which
may inﬂuence these ﬁndings. We were not able to identify
factors that affected the choice of surgical or endovascular
treatment or changes in medical therapy and critical care
because of the retrospective design. Even by combining
the experiences at two large medical centers, the small
number of patients and differences in surveillance restricts
the analysis of speciﬁc factors associated with morbidity,
mortality, graft patency, recurrent stenosis, and reinterven-
tions. For example, the lower primary patency in patients
treated by R-OR is likely a reﬂection of multiple factors,
including more advanced mesenteric disease, a more distal
mesenteric target, and other possible medical factors that
negatively affect patency. Finally, the low morbidity and
mortality with elective mesenteric R-ORs emphasizes the
importance of proper patient selection and surgical
experience.
CONCLUSIONS
This study demonstrates that mesenteric R-ORs and
ERs for failing grafts are safe provide reasonable early
patency and equivalent secondary patency to ﬁrst-time in-
terventions. Surveillance of the reconstruction is critical,
because the only patient deaths in this series occurred
from graft thrombosis causing AMI. The choice ofapproach and outcomes are inﬂuenced by physician prefer-
ence and experience, location and extent of disease, and
whether there is stenosis or occlusion of the mesenteric
graft. Patients with graft thrombosis and those with acute
symptoms are often not candidates for ER and need R-
OR. In these patients, an intraoperative ultrasound assess-
ment and careful follow-up is recommended because of
lower patency rates. Primary stenting or angioplasty should
be considered the ﬁrst treatment option when possible
because of lower morbidity and similar rates of restenosis
and reintervention compared with R-OR. Finally, the early
outcomes of mesenteric R-ORs are similar to those
achieved with the ﬁrst index surgical procedure.AUTHOR CONTRIBUTIONS
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Supplementary Fig 1 (online only). Kaplan-Meier survival esti-
mates of freedom from symptom recurrence in patients treated by
redo open reconstruction (R-OR, blue line) or ﬁrst-time OR (red
line) for chronic mesenteric ischemia (CMI). The dotted line in-
dicates standard deviation >10%.
Supplementary Fig 2 (online only). Kaplan-Meier survival esti-
mates of freedom from reintervention in patients treated by redo
open reconstruction (R-OR, blue line) or ﬁrst-time OR (red line)
for chronic mesenteric ischemia (CMI). The dotted line indicates
standard deviation >10%.
Supplementary Fig 3 (online only). Kaplan-Meier survival esti-
mates of primary patency in patients treated by redo open
reconstruction (R-OR, blue line) or ﬁrst-time OR (red line) for
chronic mesenteric ischemia (CMI). The dotted line indicates
standard deviation >10%.
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Supplementary Table (online only). Case-control matched comparison of ﬁrst-time mesenteric open reconstruction
(OR) and reoperative OR (R-OR) for chronic mesenteric ischemia (CMI).
Variable
ORs (n ¼ 35) R-ORs (n ¼ 19)
P valueNo. (%) or mean 6 SD
Age, years 58 6 9 57 6 8 .66
Female gender 27 (77) 18 (95) .13
Cardiovascular risk factors
Tobacco 32 (92) 15 (79) .23
Hypertension 18 (51) 12 (63) .57
Hyperlipidemia 17 (49) 10 (53) 1.00
PVD 11 (31) 4 (21) .53
CAD 6 (17) 4 (21) .73
CVD 5 (14) 1 (5) .41
COPD 6 (16) 3 (16) 1.00
Renal failure 1 (3) 1 (5) 1.00
Diabetes 1 (3) 1 (5) 1.00
CHF 0 (0) 0 (0)
Dialysis 0 (0) 0 (0)
Outcomes
30-day
Mortality 1 (3) 0 (0) 1.00
Morbidity 14 (40) 12 (63) .15
1-year
Freedom from recurrence, % 97 6 3 88 6 8 .21
Freedom from reintervention, % 93 6 5 77 6 10 .06
Primary patency, % 93 6 5 66 6 12 .006
Secondary patency, % 100 6 0 100 6 0 1.00
CAD, Coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; PVD, peripheral
vascular disease; SD, standard deviation.
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